Replimune Group (REPL) News Today $12.34 -0.15 (-1.20%) (As of 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?Replimune Group (NASDAQ:REPL) Shares Gap Up - Here's WhyDecember 23 at 12:07 PM | marketbeat.comReplimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23 at 8:00 AM | globenewswire.comState Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL)State Street Corp boosted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 102.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,340,042 shares of the company's stock after purchasing an additional 1,182,181 sDecember 23 at 3:26 AM | marketbeat.comJane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL)Jane Street Group LLC cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 51.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 262,248 shares of the company's stock after selling 274,078 shDecember 22 at 3:40 AM | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 8.2% - Here's WhyReplimune Group (NASDAQ:REPL) Trading Up 8.2% - Here's What HappenedDecember 20 at 3:27 PM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel Sells 10,000 SharesDecember 19, 2024 | insidertrades.comInsider Selling: Replimune Group, Inc. (NASDAQ:REPL) CEO Sells 10,000 Shares of StockReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.December 18, 2024 | marketbeat.comWellington Management Group LLP Decreases Position in Replimune Group, Inc. (NASDAQ:REPL)Wellington Management Group LLP reduced its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 40.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 242,398 shares of thDecember 18, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Trading Down 4.7% - Here's WhyReplimune Group (NASDAQ:REPL) Shares Down 4.7% - Should You Sell?December 17, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in NovemberReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily trading volume, of 828,800 shares, the short-interest ratio is currently 6.7 days.December 14, 2024 | marketbeat.comFmr LLC Sells 120,776 Shares of Replimune Group, Inc. (NASDAQ:REPL)Fmr LLC trimmed its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 16.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 626,412 shares of the company's stock after selling 120,776 shares duriDecember 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 52,498 Shares of Replimune Group, Inc. (NASDAQ:REPL)Charles Schwab Investment Management Inc. grew its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 12.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 484,797 shares of the company's stock after acquiring an additional 52,498 shares during tDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 44,153 Shares of Replimune Group, Inc. (NASDAQ:REPL)Jacobs Levy Equity Management Inc. cut its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 52.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 39,521 shares ofDecember 10, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Buy" from AnalystsShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been assigned an average rating of "Buy" from the eight brokerages that are covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to theDecember 7, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Replimune Group (REPL)December 5, 2024 | markets.businessinsider.comReplimune Group, Inc. (NASDAQ:REPL) is Redmile Group LLC's 8th Largest PositionRedmile Group LLC lessened its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 14.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,781,183 shares of the company's stock aDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $8.37 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)Parkman Healthcare Partners LLC grew its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 45.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 763,747 shares of the company's stock after aDecember 4, 2024 | marketbeat.comBaker BROS. Advisors LP Has $121.06 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)Baker BROS. Advisors LP boosted its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 10.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,045,336 shares of the company's stock after acquDecember 2, 2024 | marketbeat.comAlgert Global LLC Has $469,000 Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)Algert Global LLC lowered its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 49.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 42,763 shares of the company's stock after seDecember 1, 2024 | marketbeat.comBraidwell LP Has $33.66 Million Holdings in Replimune Group, Inc. (NASDAQ:REPL)Braidwell LP raised its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 203.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,070,837 shares of the company's stock after acquiring an additionNovember 29, 2024 | marketbeat.comReplimune: RPL1 BLA Submission Under AA Pathway Makes It A Must WatchNovember 29, 2024 | seekingalpha.comReplimune 6.923M share Spot Secondary priced at $13.00November 26, 2024 | markets.businessinsider.comReplimune Prices Public Offering Of 6.923 Mln Common Shares At $13/ShrNovember 26, 2024 | markets.businessinsider.comReplimune Announces Pricing of Upsized Public OfferingNovember 25, 2024 | globenewswire.comOptimistic Buy Rating for Replimune Group Amid Promising Developments in Melanoma TreatmentNovember 25, 2024 | markets.businessinsider.comReplimune Announces Proposed Public OfferingNovember 25, 2024 | globenewswire.comReplimune price target raised to $18 from $14 at BMO CapitalNovember 23, 2024 | markets.businessinsider.comBuy Recommendation for Replimune Group: Promising Developments and Clinical Results of RP1 TreatmentNovember 23, 2024 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Hits New 12-Month High After Analyst UpgradeReplimune Group (NASDAQ:REPL) Reaches New 1-Year High on Analyst UpgradeNovember 22, 2024 | marketbeat.comBMO Capital Markets Raises Replimune Group (NASDAQ:REPL) Price Target to $18.00BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a report on Friday.November 22, 2024 | marketbeat.comReplimune's stock surges 19% after-hours on FDA BLA submissionNovember 22, 2024 | msn.comReplimune Group (NASDAQ:REPL) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday.November 22, 2024 | marketbeat.comReplimune Group (REPL) Receives a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comReplimune Shares Top 52-Week High After Submitting Application for Melanoma TreatmentNovember 21, 2024 | marketwatch.comReplimune Group Advances Cancer Treatment with FDA SubmissionNovember 21, 2024 | markets.businessinsider.comReplimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval PathwayNovember 21, 2024 | globenewswire.comInsider Selling: Replimune Group, Inc. (NASDAQ:REPL) Insider Sells 7,246 Shares of StockNovember 21, 2024 | insidertrades.comReplimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLPLMR Partners LLP increased its stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 145.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,479 shares of the company's stock after purchasing an addNovember 20, 2024 | marketbeat.comReplimune Group Q3 EPS Estimate Boosted by HC WainwrightReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Stock analysts at HC Wainwright upped their Q3 2025 earnings per share estimates for shares of Replimune Group in a note issued to investors on Tuesday, November 12th. HC Wainwright analyst R. Burns now expects that the company will post earningNovember 15, 2024 | marketbeat.comReplimune Group Q3 EPS Forecast Lowered by Leerink PartnrsReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Leerink Partnrs lowered their Q3 2025 earnings per share estimates for Replimune Group in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings per share of ($0.71) fNovember 15, 2024 | marketbeat.comQ3 Earnings Estimate for Replimune Group Issued By WedbushReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities research analysts at Wedbush upped their Q3 2025 earnings per share (EPS) estimates for Replimune Group in a note issued to investors on Tuesday, November 12th. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.November 15, 2024 | marketbeat.comReplimune Group’s Q3 2024 Financial HighlightsNovember 15, 2024 | markets.businessinsider.comReplimune Group’s Strategic Progress and Financial Strength Justify Buy Rating and Increased Price TargetNovember 15, 2024 | markets.businessinsider.comReplimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global UncertaintiesNovember 13, 2024 | markets.businessinsider.comReplimune Group’s Strategic Progress and Positive Outlook in Regulatory and Market PreparationsNovember 13, 2024 | markets.businessinsider.comReplimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate UpdateNovember 12, 2024 | finance.yahoo.comReplimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by AnalystsReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendationNovember 12, 2024 | marketbeat.comReplimune Group (NASDAQ:REPL) Sets New 1-Year High - Should You Buy?Replimune Group (NASDAQ:REPL) Reaches New 12-Month High - Here's WhyNovember 11, 2024 | marketbeat.comReplimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)November 9, 2024 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 8, 2024 | globenewswire.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown. REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.800.60▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼103▲REPL Articles Average Week Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Janux Therapeutics News Merus News Xenon Pharmaceuticals News Zai Lab News Twist Bioscience News Edgewise Therapeutics News MorphoSys News ACADIA Pharmaceuticals News Vericel News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
